Medical Device Market Access for Thailand, Indonesia, and the Philippines

The medical device markets of Thailand, Indonesia, and the Philippines continue to grow as the region’s expanding healthcare ecosystem attracts growing interest from global manufacturers. Cisema supports companies seeking market entry into Thailand, Indonesia, and the Philippines—three high-growth Southeast Asian markets with large populations, rising healthcare investments, and evolving regulatory frameworks. Our services focus on regulatory approvals and feasibility support for successful long-term entry. This article reviews each of the Thai, Indonesian and Philippines medical devices markets in brief before summarising license fee data for each.

Thailand: Established Medical Tourism and Healthcare Innovation Agenda

Thailand is ranked among the top five medical tourism destinations globally, with over 3.5 million foreign patients annually, supported by private hospital excellence and international care standards. According to World Journal of Advanced Research and Reviews, Thailand remains a top destination for global patients. The government’s Thailand Board of Investment promotes healthcare innovation hubs under the “Thailand 4.0” strategy, enhancing infrastructure for medical devices and digital health systems.

Cisema provides regulatory intelligence, classification guidance, and market feasibility analysis in Thailand. We help manufacturers evaluate registration pathways, understand documentation requirements, and align early-stage strategy with the Thai FDA process.

Indonesia: Population Scale and Insurance-Driven Procurement Growth

Indonesia is the fourth most populous country in the world, with a population exceeding 277 million. According to the World Bank, the population surge is matched by increasing healthcare demand. Its healthcare system is experiencing significant growth, driven by an expanding healthcare infrastructure and an increasing focus on improving patient outcomes.

According to Statista, the medical device market is projected to reach approximately USD 3.51 billion by 2030, with an annual growth rate of 9.18% during the period from 2025 to 2030. Among the segments, cardiology devices are anticipated to be the largest, with a projected market volume of USD 336.47 million.

Cisema offers country-specific regulatory guidance, feasibility assessments, and strategic dossier planning for manufacturers evaluating entry into Indonesia. Our team provides insights into classification logic, ASEAN harmonization, and submission procedures under the Indonesian Ministry of Health.

Philippines: Universal Health Coverage and Regulatory Alignment

The Philippines offers a highly accessible regulatory environment with strong alignment to CE Mark and US FDA frameworks. Regulatory reforms such as FDA Circular No. 2021-001A, which streamlines registration by accepting prior approvals from reference markets and aligns submissions with the ASEAN Common Submission Dossier Template (CSDT), support ASEAN technical harmonization.

The market is expected to grow at a compound annual growth rate (CAGR) of 9.66%, reaching approximately US$1.16 billion by 2030. This growth is driven by rising demand for advanced imaging technologies to enhance diagnostic capabilities and support healthcare modernization efforts. For more detailed insights, see Statista.

Cisema supports manufacturers entering the Philippines by providing regulatory intelligence, classification review, and early-stage strategic planning. Our team advises on document preparation, ASEAN CSDT alignment, and registration feasibility under the Philippine FDA.

What Cisema Provides Across All Three Countries

 
• Regulatory intelligence and policy landscape analysis
 
• Country-specific classification advisory
 
• Feasibility assessments for future product registration
 
• Strategic consultation for market entry planning
 
• Support with ASEAN CSDT formatting and document review

These services help manufacturers lay the groundwork for effective market entry by identifying regulatory risks, understanding classification logic, and aligning dossier strategies with local expectations.

Market Comparison Snapshot

CountryDevice Classes CoveredAvg. Registration TimePopulation (2024 est.)Medical Device Market Size (2030 est.)ThailandClass 1–46–9 months71 millionUSD 3.43 billion*IndonesiaClass A–D3–5 months277 millionUSD 3.51 billion**PhilippinesClass A–D9–12 months117 millionUSD 1.16 billion***Data Sources:
* Statista – Thailand Medical Devices Market Size (2030)
** Statista – Indonesia Medical Devices Market Size (2030)
*** Statista – Philippines Medical Devices Market Size (2030)

Medical Device Application and Licensing Fee Comparison

CountryDevice ClassApplication FeeRegistration FeeAdditional NotesThailandClass 1THB 500 (US$ 17)THB 2,000 (US$ 66)No specialist review requiredClass 2THB 1,000 (US$ 33)THB 10,000 (US$ 330)+THB 38,000 if no HSA/referenceClass 3THB 1,000 (US$ 33)THB 10,000 (US$ 330)+THB 38,000 if no HSA/referenceClass 4THB 1,000 (US$ 33)THB 20,000 (US$ 660)+THB 53,000 if no HSA/referenceIndonesiaClass AIDR 1,500,000 (~USD 100)IncludedLow-riskClass BIDR 3,000,000 (~USD 200)IncludedModerate-riskClass CIDR 3,000,000 (~USD 200)IncludedHigh-riskClass DIDR 5,000,000 (~USD 340)IncludedHighest-riskPhilippinesClass APHP 1,515Included (5-year validity)Unified annual fee applies across all classesClass BClass CClass D* Thailand: Specialist review fees apply only if the device lacks reference approvals (e.g., US FDA, HSA).
* Thailand, Indonesia and Philippines: Fees are indicative and may vary due to product category or exchange rates.

Meet the Cisema Team at WHX Labs Kuala Lumpur

Cisema will participate in WHX Labs Kuala Lumpur during the World Health Expo from July 16 to July 18, 2025. If your organization is exploring Southeast Asia market expansion—particularly Thailand, Indonesia, or the Philippines—this event offers a unique opportunity to speak directly with our experts and shape your regional strategy.

Link to the event: WHX Labs Kuala Lumpur

Further Information

Cisema is your embedded regulatory partner across ASEAN. With established local infrastructure, we provide manufacturers with market intelligence, classification strategy, and early registration planning tailored to Thailand, Indonesia, and the Philippines.

To learn more or begin your feasibility evaluation, visit our country-specific service pages:

 
• Thailand
 
• Indonesia
 
• Philippines

If you're a medical device manufacturer with questions about regulatory strategy, timelines, or ASEAN alignment, contact Cisema for tailored insights and expert support.

About the Author: Shouzheng Tan

Shouzheng Tan is Vice President of Southeast Asia at Cisema, based in Penang, Malaysia. He brings more than a decade of experience in the medical device industry, specializing in regulatory registration and market access across Southeast Asia. In his role, he works closely with overseas manufacturers to develop and implement effective regulatory strategies for medical devices throughout the region, including key markets such as Malaysia. His expertise is complemented by working knowledge of quality management systems, allowing him to support clients across both regulatory and compliance requirements.